Products
News
Resources
Contact
Language
简体中文
繁體中文
English
日本語
한국어
Tiếng Việt
Overview
Latest
Regional
Industry
Featured
Multimedia
Other Languages
Public Company News
All
APAC
Global
All
APAC
Global
All
APAC
Global
All
APAC
Global
{{toptitleLeft}}
{{toptitleRight}}
{{selectTitle}}
{{toptitleLeft}}
{{index}}
{{select_list_per.name}}
Time
{{showName}}
{{weixin_name}}
X
{{listname}}
Loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.headline}}
{{storydata.create_time}}
{{storydata.headline}}
{{storydata.create_time}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
loading
The End
Network Errors Please Retry
Telix and Wiik Pharma Sign Distribution Agreement for Illuccix® in the Nordic Region
2023-11-08 13:00
ProstACT SELECT Study of TLX591 Interim Readout: Positive Results Confirm Safety and Tolerability
2023-10-19 06:01
Telix reports fourth consecutive quarter of positive operating cash flow
2023-10-18 15:42
HRH Princess Astrid of Belgium visits Telix's New European Manufacturing Facility in Brussels South
2023-09-27 12:00
Telix to Showcase New ZIRCON Phase III Kidney Cancer Imaging Data and Theranostic Pipeline at EANM
2023-09-06 14:18
Telix 2023 Half-Year Results: Revenue and Earnings Growth Marks Transition to a Sustainable Commercial-Stage Company
2023-08-23 17:40
First Patient Dosed in Pivotal Phase III Study of TLX591-CDx (Illuccix®) for Prostate Cancer Imaging in Chinese Patients
2023-08-11 11:14
First Patient Dosed in Pivotal Phase III Study of TLX591-CDx (Illuccix®) for Prostate Cancer Imaging in Chinese Patients
2023-08-11 07:18
First Patient Dosed in IPAX-2 Study of TLX101 Brain Cancer Therapy Candidate in Patients with Newly Diagnosed Glioblastoma
2023-08-08 06:24
Telix Reports Continued Double-Digit Revenue Growth and Positive Operating Cash Flow
2023-07-19 16:14
First Patient Dosed in STARSTRUCK Study of TLX250 Targeted Radiation Therapy in Combination with Merck Investigational DNA-PK Inhibitor, Peposertib
2023-07-19 05:00
New ZIRCON Phase III Data Presented at SNMMI: Potential Utility of TLX250-CDx in Staging and Monitoring ccRCC
2023-06-27 03:51
Telix to Showcase ZIRCON Phase III Kidney Cancer Imaging Data and Theranostic Pipeline Developments at SNMMI
2023-06-22 19:00
Telix to Expand Late-Stage Urologic Pipeline with Acquisition of Lightpoint Medical
2023-06-21 17:32
Telix Urology Innovation Showcase to be held at The Yale Club, New York City
2023-06-21 06:31
First Patient Dosed in Phase II STARBURST Study of TLX250-CDx Exploring Indication Expansion
2023-06-19 08:16
Telix Briefing: Innovation in Urology to Feature Key Opinion Leaders in Prostate and Kidney Cancer
2023-06-15 19:00
Telix Opens European Radiopharmaceutical Production Facility
2023-06-08 20:00
Telix to Present at Jefferies Healthcare Conference
2023-06-06 08:40
Telix to Host Briefing with U.S. Leadership Team and Key Opinion Leaders to Highlight Innovation in Urology
2023-05-25 19:00
1
2
3
4
5
6